[HTML][HTML] Anti-VEGF therapy in refractory pituitary adenomas and pituitary carcinomas: a review
C Dai, S Liang, B Sun, Y Li, J Kang - Frontiers in Oncology, 2021 - frontiersin.org
Most pituitary tumors are considered benign adenomas, and only 0.1%–0.2% of them
present metastasis and are defined as pituitary carcinomas (PCs). Refractory pituitary …
present metastasis and are defined as pituitary carcinomas (PCs). Refractory pituitary …
Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review.
C Dai, S Liang, B Sun, Y Li, J Kang - Frontiers in Oncology, 2021 - europepmc.org
Most pituitary tumors are considered benign adenomas, and only 0.1%–0.2% of them
present metastasis and are defined as pituitary carcinomas (PCs). Refractory pituitary …
present metastasis and are defined as pituitary carcinomas (PCs). Refractory pituitary …
[HTML][HTML] Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review
C Dai, S Liang, B Sun, Y Li, J Kang - Frontiers in Oncology, 2021 - ncbi.nlm.nih.gov
Most pituitary tumors are considered benign adenomas, and only 0.1%–0.2% of them
present metastasis and are defined as pituitary carcinomas (PCs). Refractory pituitary …
present metastasis and are defined as pituitary carcinomas (PCs). Refractory pituitary …
Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review
C Dai, S Liang, B Sun, Y Li… - Frontiers in oncology, 2021 - pubmed.ncbi.nlm.nih.gov
Most pituitary tumors are considered benign adenomas, and only 0.1%-0.2% of them
present metastasis and are defined as pituitary carcinomas (PCs). Refractory pituitary …
present metastasis and are defined as pituitary carcinomas (PCs). Refractory pituitary …
[引用][C] 1. Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review
C Dai - spandidos-publications.com
[引用][C] Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review
C Dai - Front Oncol, 2021 - cir.nii.ac.jp
Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review. Front
C Dai, S Liang, B Sun, Y Li, J Kang - Recent Advances in the …, 2022 - books.google.com
Most pituitary tumors are considered benign adenomas, and only 0.1%–0.2% of them
present metastasis and are defined as pituitary carcinomas (PCs). Refractory pituitary …
present metastasis and are defined as pituitary carcinomas (PCs). Refractory pituitary …
Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review.
C Dai, S Liang, B Sun, Y Li, J Kang - Frontiers in Oncology, 2021 - europepmc.org
Most pituitary tumors are considered benign adenomas, and only 0.1%–0.2% of them
present metastasis and are defined as pituitary carcinomas (PCs). Refractory pituitary …
present metastasis and are defined as pituitary carcinomas (PCs). Refractory pituitary …